What sector does Johnson & Johnson belong to?

Johnson & Johnson operates in the Health Care sector, specifically the Pharmaceuticals industry, and is listed on the US markets.

What is the current share price of JNJ?

As of the latest available quote, JNJ traded at $265.58. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of JNJ?

Johnson & Johnson has a price-to-earnings (P/E) ratio of about 30.77. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of JNJ?

The market capitalisation of Johnson & Johnson is approximately $645.39B.

Is Johnson & Johnson profitable?

For its latest reported financial year, Johnson & Johnson recorded a net profit margin of about 28.46%.

Does JNJ pay a dividend?

Johnson & Johnson currently has a dividend yield of about 1.97%.

What is the return on equity (ROE) of JNJ?

Johnson & Johnson has a return on equity (ROE) of about 31.54%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of JNJ?

Over the past 52 weeks, JNJ has traded between a low of $173.33 and a high of $281.07.

Johnson & Johnson

JNJ US Health Care Pharmaceuticals

S&P 500 Dow Jones

$265.58

-0.29%

Delayed · cached 15 min

Fair value analysis

JNJ

Johnson & Johnson

$265.58

Close used for this calculation

$200.76Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

60/100

Profitability21/25

Returns13/25

Balance Sheet15/25

Efficiency11/25

Growth9/25

Good

Quality radar

Consensus fair value

$200.76

Above FV

▼ -24.4% against the close used

Model range $92.94 – $278.22

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$92.94Fair value$200.76Bull$278.22

FairClose

52-week traded range

52W low $174.1652W high $278.43

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Johnson & Johnson closed at $265.58, 32.3% above the consensus fair value of $200.76 drawn from 9 valuation models.

Financial DNA score 60/100 — Good. P/E of 24.1x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

$160.89

-39.4%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

$92.94

-65.0%

√(22.5 × EPS × BVPS)

EPS=11.03, BVPS=34.81 · outside Graham range (P/E 24.1, P/B 7.6) — asset-light, treat as a rough floor

P/E Fair Value

$220.60

-16.9%

EPS × 20x (sector P/E)

EPS=11.03, Sector P/E=20x

Peter Lynch (PEG)

$110.52

-58.4%

EPS × Growth% (PEG = 1 is fair)

EPS=11.03, g=10%

EV/EBITDA

$238.65

-10.1%

(EBITDA × 15x − Net Debt) ÷ Shares

EBITDA=40.08B

Dividend Discount (DDM)

$278.22

+4.8%

D1 ÷ (r − g) where D1 = D0×(1+g)

D0=5.15, r=10%, g=8%

Book Value (P/B)

$222.24

-16.3%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=34.81, ROE=31.5%, g=6%, r=10%

Reverse DCF

$265.58

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 9.6% | Historical: 10%

Margin of Safety

$118.61

-55.3%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=158.14, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer